Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

"Switching Partners": Piperacillin-Avibactam Is a Highly Potent Combination against Multidrug-Resistant Burkholderia cepacia Complex and Burkholderia gladioli Cystic Fibrosis Isolates.

Zeiser ET, Becka SA, Wilson BM, Barnes MD, LiPuma JJ, Papp-Wallace KM.

J Clin Microbiol. 2019 Jul 26;57(8). pii: e00181-19. doi: 10.1128/JCM.00181-19. Print 2019 Aug.

PMID:
31167848
2.

Ceftazidime-Avibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy Against Multidrug-Resistant Pseudomonas aeruginosa.

Papp-Wallace KM, Zeiser ET, Becka SA, Park S, Wilson BM, Winkler ML, D'Souza R, Singh I, Sutton G, Fouts DE, Chen L, Kreiswirth BN, Ellis-Grosse EJ, Drusano GL, Perlin DS, Bonomo RA.

J Infect Dis. 2019 May 17. pii: jiz149. doi: 10.1093/infdis/jiz149. [Epub ahead of print]

PMID:
31099835
3.

Resurrecting Old β-Lactams: Potent Inhibitory Activity of Temocillin against Multidrug-Resistant Burkholderia Species Isolates from the United States.

Zeiser ET, Becka SA, Barnes MD, Taracila MA, LiPuma JJ, Papp-Wallace KM.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02315-18. doi: 10.1128/AAC.02315-18. Print 2019 Apr.

PMID:
30718248
4.

Characterization of the AmpC β-Lactamase from Burkholderia multivorans.

Becka SA, Zeiser ET, Barnes MD, Taracila MA, Nguyen K, Singh I, Sutton GG, LiPuma JJ, Fouts DE, Papp-Wallace KM.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01140-18. doi: 10.1128/AAC.01140-18. Print 2018 Oct.

5.

Sequence heterogeneity of the PenA carbapenemase in clinical isolates of Burkholderia multivorans.

Becka SA, Zeiser ET, Marshall SH, Gatta JA, Nguyen K, Singh I, Greco C, Sutton GG, Fouts DE, LiPuma JJ, Papp-Wallace KM.

Diagn Microbiol Infect Dis. 2018 Nov;92(3):253-258. doi: 10.1016/j.diagmicrobio.2018.06.005. Epub 2018 Jun 18.

6.

Relebactam Is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae.

Papp-Wallace KM, Barnes MD, Alsop J, Taracila MA, Bethel CR, Becka SA, van Duin D, Kreiswirth BN, Kaye KS, Bonomo RA.

Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e00174-18. doi: 10.1128/AAC.00174-18. Print 2018 Jun.

7.

Inactivation of the Pseudomonas-Derived Cephalosporinase-3 (PDC-3) by Relebactam.

Barnes MD, Bethel CR, Alsop J, Becka SA, Rutter JD, Papp-Wallace KM, Bonomo RA.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02406-17. doi: 10.1128/AAC.02406-17. Print 2018 May.

8.

Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients.

Papp-Wallace KM, Becka SA, Zeiser ET, Ohuchi N, Mojica MF, Gatta JA, Falleni M, Tosi D, Borghi E, Winkler ML, Wilson BM, LiPuma JJ, Nukaga M, Bonomo RA.

ACS Infect Dis. 2017 Jul 14;3(7):502-511. doi: 10.1021/acsinfecdis.7b00020. Epub 2017 Mar 30.

9.

Exploring the Role of the Ω-Loop in the Evolution of Ceftazidime Resistance in the PenA β-Lactamase from Burkholderia multivorans, an Important Cystic Fibrosis Pathogen.

Papp-Wallace KM, Becka SA, Taracila MA, Zeiser ET, Gatta JA, LiPuma JJ, Bonomo RA.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01941-16. doi: 10.1128/AAC.01941-16. Print 2017 Feb.

10.

Exposing a β-Lactamase "Twist": the Mechanistic Basis for the High Level of Ceftazidime Resistance in the C69F Variant of the Burkholderia pseudomallei PenI β-Lactamase.

Papp-Wallace KM, Becka SA, Taracila MA, Winkler ML, Gatta JA, Rholl DA, Schweizer HP, Bonomo RA.

Antimicrob Agents Chemother. 2015 Nov 23;60(2):777-88. doi: 10.1128/AAC.02073-15. Print 2016 Feb.

Supplemental Content

Loading ...
Support Center